Business
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023
Promising Updated Phase II Data Presented at ASCO 2023 for Ivonescimab First US Patient Treated in Ivonescimab Phase III Clinical Trial with the First
About this update from Summit Therapeutics Inc.
[{"type":"text","content":"\nPromising Updated Phase II Data Presented at ASCO 2023 for Ivonescimab\n\n\nFirst US Patient Treated in Ivonescimab Phase III Clinical Trial with the First Patient in Ivonescimab's Second Phase III Clinical Trial Planned for the Second Half of 2023\n\n\n MENLO PARK, Calif.--(BUSINESS WIRE)--\nSummit Therapeutics Inc. (NASDAQ: SMMT) (\"Summit,\" \"we,\" or the \"Company\") today reports its financial results and provides an update on operational progress for the second quarter and six months ended June 30, 2023.\n\n\nOperational & Corporate Updates\n\n\n\nOur operational progress with ivonescimab (SMT112), an innovative, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule:\n\n\nSummit is actively engaged in development activities for SMT112. In just over six months since we closed our in-licensing transaction for ivonescimab, Summit has:\n\n\nHeld multiple meetings with the US Food & Drug Administration (FDA) regarding its planned Phase III clinical program and incorporated this feedback accordingly, and\n\n\n\nBegun its clinical development in non-small cell lung cancer (NSCLC) in the following indications:\n\n\nIvonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) (“HARMONi” trial)\n\n\n\nIvonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (“HARMONi-3” trial)\n\n\n\n\n\n\n\n\n\nIn May 2023, the first patient in Summit's license territories was treated in the Phase III HARMONi clinical trial.\n\n\nSummit intends to dose patients in the HARMONi-3 trial during the second half of 2023.\n\n\n\n\n\n\nIn June 2023, promising Phase II data from AK112-201, a study of Chinese subjects conducted and analyzed by our partners, Akeso, was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. In addition to encouraging data in multiple indications within NSCLC, a portion of the updated data presented at ASCO supports Summit's HARMONi-3 clinical trial in first-line metastatic squamous NSCLC: Phase II data in 63 treatment-naive, squamous NSCL...